Aveo Pharmaceuticals, Inc.

Steven Tyler

Jeno Gyuris

Kristan Meetze

Sylvie Vincent

Steve Bottega

Ting Chen

William M Winston, Jr

Lyne Breault

Solly Weiler

Fang Wang

Michael DePrima

Christina Fleet

Jin-Kyeung Woo

Bin Feng

Richard Nicoletti

Donna McIntosh

Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.

Anti-ErbB3 antibodies

Anti-ERBB3 antibodies

A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.

Predicting tumor response to anti-ERBB3 antibodies

Growing community of inventors

Boston, MA, United States of America

Steven Tyler